XML 46 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Agreements - Debiopharm (Details) - USD ($)
3 Months Ended 9 Months Ended
May 24, 2017
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Collaborative Agreements disclosures          
License and milestone fees   $ 79,000 $ 76,000 $ 49,889,000 $ 10,229,000
Research and development support   650,000 $ 1,354,000 3,030,000 $ 3,748,000
Debiopharm          
Collaborative Agreements disclosures          
Payments received under collaboration agreement $ 25,000,000        
Potential milestone payments 5,000,000        
Fair value of consideration for services provided 30,000,000        
License and milestone fees 29,700,000        
Research and development support 300,000        
Remaining arrangement consideration to be recognized as license revenue   $ 25,000,000   $ 25,000,000  
Debiopharm | Phase 3 Clinical Trial          
Collaborative Agreements disclosures          
Potential milestone payments $ 25,000,000